Delivery Order SPE2DB20D3103-SPE2DB25FP9M6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,485.29 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen injections, 40 mg/0.4 mL. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 31, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication prescribed for autoimmune conditions including...
- The Defense Logistics Agency awarded a $7,022.45 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-competitive delivery order is issued under a firm fixed-price arrangement and represents a single pharmaceutical supply transaction sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic immunosuppressant used to...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL doses. This is a firm fixed price delivery order with no set-aside designation, demonstrating that the award was competitively procured. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. HUMIRA is a widely...
- The Defense Logistics Agency awarded a delivery order valued at $5,857.24 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product...
- The Defense Logistics Agency awarded a delivery order valued at $1,482.94 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on August 12, 2025, with completion targeted for August 13, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic immunosuppressant medication commonly prescribed for rheumatoid arthritis,...
- The Defense Logistics Agency has awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40 mg/0.8 mL units. This competitively awarded, firm fixed price contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication for treating autoimmune conditions including rheumatoid arthritis,...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA Pen 40mg/4mL (2 pens) with a ceiling value of $26,615.29. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. HUMIRA...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a firm fixed-price delivery order valued at $12,837.62 for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This contract award, issued on July 30, 2025, represents a non-competitive child delivery order under an existing indefinite delivery contract vehicle. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 31, 2025. HUMIRA is a widely used...
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $20,192.93 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order represents a non-competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely-used immunosuppressant medication used to treat autoimmune conditions including rheumatoid...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP9M6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,497.68 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL on August 19, 2025, with completion targeted for August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic immunosuppressant medication prescribed for various autoimmune conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease, making it a critical pharmaceutical product for military and federal healthcare beneficiaries. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical prime vendor agreement extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare systems. The company's demonstrated capability to compete and win federal contracts, combined with its extensive pharmaceutical portfolio, positions it as a key supplier for Defense Health Agency requirements and other government healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 8/19/25 |